Methylphenidate is the first-choice medication for the treatment of ADHD in children and adolescents. Over the past two decades, several randomised controlled trials re-peatedly showed its efficacy on both the core symptoms and the quality of life besides its tolerability in the short term. The most common adverse effects include sleep disturb-ance, nervous- ness, reduced appetite, weight loss, headache, elevated blood pressure and heart rate. These effects are generally mild, transient and easily manageable by clinicians. Despite the reassuring data in terms of short-term safety and tolerability, some questions still re- main open with respect to the treatment effects in the long term. In the meantime it is however appropriate to continue to refer to the current European clinical practice guide- lines. The paper reports treatment indications, information about the mechanism of action, the Italian available formulations and the answers to the most frequent questions for a correct clinical and pharmacological monitoring of young patients.

Methylphenidate and ADHD|Metilfenidato e ADHD

Carucci S.
2021-01-01

Abstract

Methylphenidate is the first-choice medication for the treatment of ADHD in children and adolescents. Over the past two decades, several randomised controlled trials re-peatedly showed its efficacy on both the core symptoms and the quality of life besides its tolerability in the short term. The most common adverse effects include sleep disturb-ance, nervous- ness, reduced appetite, weight loss, headache, elevated blood pressure and heart rate. These effects are generally mild, transient and easily manageable by clinicians. Despite the reassuring data in terms of short-term safety and tolerability, some questions still re- main open with respect to the treatment effects in the long term. In the meantime it is however appropriate to continue to refer to the current European clinical practice guide- lines. The paper reports treatment indications, information about the mechanism of action, the Italian available formulations and the answers to the most frequent questions for a correct clinical and pharmacological monitoring of young patients.
2021
Methylphenidate; Child and adolescent psychopharmacology; ADHD; Efficacy; Tolerability
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/343435
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact